% | $
Quotes you view appear here for quick access.

Momenta Pharmaceuticals Inc. Message Board

  • t57776 t57776 Jan 25, 2012 5:05 AM Flag

    nvs 4th

    Sandoz net sales of USD 2.3 billion were down 5% (-4% cc) in the fourth quarter, impacted by additional competition to enoxaparin. Enoxaparin, our first generic blockbuster, achieved sales of USD 1.0 billion in 2011 (USD 225 million in the fourth quarter).

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • it'll be real interesting to see how different analysts apply their logic/knowledge of the formula of a possible new run rate of $900M-1.1B

      Oppenheimer has $16M as it's MNTA M-lov revenue.

      don't know what scenario/formula accounts for such low revenue.

      10 % of $160M?....crazy.

      • 1 Reply to t57776
      • I've given up trying to understand how these professional "analysts" model revenue for MNTA. With the new run rate of $900 M - $1.1 B in mLovenox sales, my Excel spreadsheet calculates a MNTA revenue at $260 M for 2012.

        Assumptions are as follows:
        Operating Margins at 68%
        NVS mLov revenue at $250 M/quarter

        Q1-2012 Profit Share 45% = $76.5M
        Q2-2012 Profit Share 45% = $76.5M
        Q3-2012 Profit Share 11% & 45% = [(135*0.11)+(170-135)*0.45] = $30.5M
        Q4-2012 Profit Share 45% = $76.5 M

12.20-0.51(-4.01%)Aug 26 4:00 PMEDT